A randomised trial of the effects of SGLT2 inhibition versus metformin on decline in renal function when used as first line therapy in type 2 diabetes [ 7/1/2021 - 6/30/2025 ]

Research Grant

Brief description Type 2 diabetes affects 5 in 100 Australians with many going on to develop serious heart and kidney complications. Sodium glucose co-transporter 2 (SGLT2) inhibitors are a new type of medicine that may provide benefit when used early in diabetes, but that are currently only used once complications have developed. This study will test the value of SGLT2 inhibitor treatment for kidney protection in Australians with newly diagnosed type 2 diabetes.

Funding Amount $3,815,693

Funding Scheme Clinical Trials and Cohort Studies Grants

Chief Investigator Prof Bruce Neal

Notes Clinical Trials and Cohort Studies Grants